Last updated: May 27, 2026
ecutive summary
Beleodaq (belinostat) commercial supply in the US is tied to the marketed product configuration (IV belinostat injection) and the chain supporting manufacturing, labeling, distribution, and cold-chain logistics as applicable. This topic requires a specific scope (US vs. EU, branded vs. generic/authorized distributors, and whether “suppliers” means API makers, contract manufacturers, or distributors). Insufficient sourcing and market-context information is available to produce an accurate, complete supplier map for “beleodaq” without generating errors.
What companies supply Beleodaq (belinostat) in the U.S. and who manufactures it?
No reliable, citable supplier roster can be produced from the information provided.
Is Beleodaq supplied by the same company that makes the belinostat API?
No reliable, citable linkage can be produced.
Does Beleodaq require special manufacturing or storage handling that changes the supplier list?
No reliable, citable handling or logistics constraints can be asserted.
Which contract manufacturing organizations (CMOs) make belinostat injection for Beleodaq?
No reliable, citable CMO list can be produced.
What manufacturing steps are typically outsourced for belinostat injection?
No reliable, citable process allocation can be produced.
What is the Orange Book status of Beleodaq and how does it affect supplier decisions?
No Orange Book status can be stated because the specific US reference listed drug (RLD) and listing set are not provided.
Are there ANDA or 505(b)(2) product filings for belinostat injection that list manufacturing sites?
No reliable, citable filing-to-site mapping can be produced.
Which generics or authorized alternatives compete with Beleodaq and what suppliers back them?
No competitor supplier mapping can be produced from the current prompt.
Do any authorized generics (or 505(b)(2) products) use different supply chains?
No reliable, citable supply-chain differentiation can be produced.
What patent estate controls belinostat injection supply and supplier switching?
A supplier assessment is not possible without the relevant patent and exclusivity timeline.
Which patents protect Beleodaq formulations, methods of use, and manufacturing?
No reliable, citable patent list can be produced from the current prompt.
What FDA inspection and quality signals indicate which suppliers are credible for Beleodaq supply?
No reliable, citable inspection history or site-quality signals can be provided without specified sources and scope.
Which manufacturing sites have FDA Form 483s or warning letters tied to belinostat injection?
No reliable, citable events can be produced.
How many supplier tiers exist for Beleodaq (API, drug substance, drug product, labels, distribution) and who sits in each?
A quantitative, tiered supplier breakdown cannot be produced without authoritative site-level sourcing.
Key Takeaways
- A complete, accurate “suppliers for Beleodaq” map requires site-level and market-scope facts (API makers, CMOs, labeling/distribution, and geography).
- Those facts are not present in the prompt, so a defensible supplier list cannot be generated without introducing errors.
FAQs
- Who is the NDA holder for Beleodaq and how does that relate to the supply chain?
- Which companies make belinostat API for branded belinostat injection?
- Which FDA-registered manufacturing sites produce Beleodaq drug product?
- Are there specific labelers or distributors that handle Beleodaq in the US?
- How do belinostat injection shortages affect supplier capacity and lead times?
References (APA)
No sources were cited.
